Trials / Recruiting
RecruitingNCT05755789
Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery
Intermittent Cefoxitin Administration Versus Loading Bolus Followed by Continuous Infusion for the Prevention of Surgical Site Infection in Colorectal Surgery: a Multicentre, Double-blind, Randomized Controlled Clinical Trial
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,000 (estimated)
- Sponsor
- Poitiers University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this prospective, multicentre, double-blind, randomized clinical trial is to compare intermittent cefoxitin administration to loading bolus followed by continuous infusion for surgical antibiotic prophylaxis in colorectal surgery. The main objective is to demonstrate the superiority of a loading dose of cefoxitin followed by continuous infusion over standard of care boluses in reducing SSI within 30 days after colorectal surgery
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Loading bolus of cefoxitin | Cefoxitin \[2g\] before incision |
| DRUG | Intermittent cefoxitin | Additional bolus of cefoxitin \[1g\] every 2 hours until the end of surgical closure |
| DRUG | Continuous infusion of placebo | Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure |
| DRUG | Continuous infusion of cefoxitin | Continuous infusion of cefoxitin \[0.5g/h\] from the end of the loading bolus until the end of surgical closure |
| DRUG | Intermittent placebo | Additional bolus of placebo every 2 hours until the end of surgical closure |
Timeline
- Start date
- 2023-06-22
- Primary completion
- 2025-05-01
- Completion
- 2025-06-01
- First posted
- 2023-03-06
- Last updated
- 2024-04-23
Locations
19 sites across 1 country: France
Source: ClinicalTrials.gov record NCT05755789. Inclusion in this directory is not an endorsement.